" class="no-js "lang="en-US"> Sanofi Archives - Page 2 of 2 - Medtech Alert
Saturday, September 13, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

New Soliqua ® Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin

A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, iGlarLixi) met its two […]

Libtayo ® (Cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted […]

Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase 2 Trial

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody […]

Sanofi Establishes Three-year Collaboration with Stanford Medicine to Accelerate Immunology Research

Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, […]

Sanofi Acquires Tidal Therapeutics

Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more